Shionogi &(OTC) SGIOY

Shionogi & Co., Ltd. is a prominent Japanese pharmaceutical company focused on the discovery, development, manufacturing, and commercialization of a wide range of medicines and medical equipment. Established in 1878, the company has a strong commitment to addressing unmet medical needs through innovative therapies.

Products and Services

• Fetroja for multi-drug resistant bacterial infections
• Xofluza, an antiviral medication for influenza
• Extensive R&D pipeline targeting various therapeutic areas

Growth Outlook

• Recent quarterly revenue reached JPY 165.46 billion, a significant increase
• Strong operating income margin of 24.34% indicates efficient operations
• Ongoing development of multiple compounds across diverse therapeutic areas

Financial Highlights

• Trailing twelve months (TTM) revenue of JPY 1.4 trillion reflects robust performance
• Net income margin of 46.79% showcases strong profitability
• Dividend yield of 2.37% provides attractive returns to shareholders

Shionogi & Co., Ltd. operates in the healthcare sector, specifically within the drug manufacturing industry, focusing on specialty and generic medications. The company has established a solid market presence with a market capitalization of approximately JPY 16.27 billion. Recent financial performance indicates a strong upward trajectory, with a notable increase in revenue and net income, reflecting effective management and strategic investments in research and development. The company's commitment to innovation is evident in its extensive pipeline, which includes treatments for various conditions, including infectious diseases, pain management, and neurological disorders. With a focus on addressing critical health challenges, Shionogi is well-positioned for continued growth and success in the pharmaceutical industry.